BioCardia, Inc. Files 8-K Report

TL;DR

BioCardia filed an 8-K on 6/10/24, confirming its Sunnyvale HQ.

AI Summary

On June 10, 2024, BioCardia, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 320 Soquel Way, Sunnyvale, California, 94085. This report is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing provides official notification of BioCardia's current reporting status and confirms its principal executive office location, which is important for investors and regulatory tracking.

Risk Assessment

Risk Level: low — This filing is a routine administrative update and does not contain significant financial or operational news.

Key Numbers

• 001-38999 — Commission File Number (Regulatory identifier for BioCardia, Inc.)
• 23-2753988 — IRS Employer Identification Number (Tax identification for BioCardia, Inc.)

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• June 10, 2024 (date) — Date of Report
• 320 Soquel Way, Sunnyvale, California, 94085 (location) — Principal executive offices
• Securities Exchange Act of 1934 (legal_document) — Governing Act

FAQ

Key Financial Figures

• $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
• $1.85 million — r total gross proceeds of approximately $1.85 million under the Company's previously disclose
• $264,000 — d capacity to issue up to an additional $264,000 of shares of its common stock (the Shar

Filing Documents

• bcda20240610_8k.htm (8-K) — 22KB
• 0001437749-24-019813.txt ( ) — 166KB
• bcda-20240610.xsd (EX-101.SCH) — 4KB
• bcda-20240610_def.xml (EX-101.DEF) — 13KB
• bcda-20240610_lab.xml (EX-101.LAB) — 17KB
• bcda-20240610_pre.xml (EX-101.PRE) — 13KB
• bcda20240610_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. During the period from April 1, 2024 to June 10, 2024, BioCardia, Inc. (the Company) sold an aggregate of 335,112 shares of its common stock at then-market prices for total gross proceeds of approximately $1.85 million under the Company's previously disclosed At The Market Offering Agreement (the Sales Agreement). Following such sales, the Company had capacity to issue up to an additional $264,000 of shares of its common stock (the Shares) under the prospectus supplement dated December 6, 2024 related to sales under the Sales Agreement, which the Company previously filed pursuant to the Company's effective Registration Statement on Form S-3 (File No. 333-275099). For additional information regarding the Sales Agreement and the Company's liquidity position, please see the Company's most recent Quarterly Report on Form 10-Q filed on May 14, 2024. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation or sale of any Shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. Date: June 10, 2024 By: /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR